Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neovasc Inc. T.NVC


Primary Symbol: NVCN

Healthcare Medical Instruments & Supplies
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Neovasc Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Post by Marketwatch22on Feb 08, 2018 6:31pm
312 Views
Post# 27530067

Upside Potential

Upside Potential There’s a lot of upside if the Reducer becomes available in the US & Canada, or if there is positive results for the Tiara under investigation in the US, Canada, and Europe. The German Institute for the Hospital Remuneration System has also awarded the Reducer NUB status 1 designation for 2018 which will hopefully result in health insurances approving the Reducer for reimbursement. “Based on the new NUB status 1 for the Neovasc Reducer, 107 German hospitals can now negotiate reimbursement coverage for the Neovasc Reducer therapy under the German health insurance system.”

I have a target price of minimum $4-5 on this stock. Any thoughts?   

Links to articles:
https://www.newswire.ca/news-releases/neovasc-announces-receipt-of-german-nub-status-1-designation-for-neovasc-reducer-procedure-for-treatment-of-refractory-angina-672115863.html

https://www.newswire.ca/news-releases/neovasc-reducer-featured-in-live-case-at-berlin-symposium-669900103.html
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities